

FUTA Journal of Research in Sciences, Vol. 13 (2), October, 2017:190-198

### SYNTHESIS, SPECTROSCOPIC CHARACTERIZATION AND ANTIOXIDANT PROPERTIES OF SOME METAL(II) COMPLEXES OF MIXED DRUGS-VITAMIN Bx AND PARACETAMOL

ADESOJI A. OLANREWAJU\*<sup>1</sup>, ADEROJU A. OSOWOLE<sup>2</sup>

\*Corresponding author: sojylanrey2009@gmail.com, Tel.: +2348038078074 <sup>1</sup> Chemistry and Industrial Chemistry Department, Bowen University, Iwo, Nigeria <sup>2</sup> Inorganic Chemistry Unit, Department of Chemistry, University of Ibadan, Ibadan, Nigeria

#### ABSTRACT

Some metal(II) complexes of mixed drugs, Vitamin Bx (p-aminobenzoic acid) and Paracetamol(N-acetyl-paminophenol), were synthesized and characterized by solubility, percentage metal, melting points, room temperature magnetic moments, conductivity, infrared and electronic spectra measurements(M = Mn, Fe, Co, Ni, Cu and Zn). Infrared data showed that the Vitamin Bx coordinated to the metal through the un-deprotonated carboxylate oxygen atoms while the Paracetamol coordinated through its carbonyl oxygen and the un-deprotonated phenolic oxygen atoms respectively. The percentage metal analysis, electronic and infrared spectra corroborated octahedral geometry. Furthermore, the room temperature magnetic moments indicated that the Mn(II) and Co(II) complexes were dimeric, the Fe(II) complex exhibited spin-cross over and the remaining metal complexes were mononuclear. The antioxidant studies on the metal complexes showed that the Co(II) and Zn(II) complexes had the best antioxidant activity of about 98 % inhibition, which was higher than that of the standard, ascorbic acid (~88%), proving their potentials as an agents which can reduce the risk for lingering diseases such as cancer and heart disease.

Keywords: Metal complexes, mixed drugs, therapeutic agents, spin-crossover, octahedral .

#### INTRODUCTION

Vitamin  $B_x$  (p-aminobenzoic acid), is a chemical substance that is found in folic acid vitamin molecule (folate). Plants, fungi and many microorganisms synthesize folate but humans and other higher animals do not (Cossins, 2000). Vitamin  $B_x$  only supports folic acid production by the intestinal bacteria in mammals. It is used (along with biotin, panthothenic acid and folic acid) in the restoration of hair, to reduce aging of the skin, lessening wrinkles and vitiligo- a skin depigmenting condition. Therefore, there is a need for dietary supply of this from several food sources such as grains, brewer's yeast, molasses, liver, eggs, milk and kidney (Cossins, 2000; Green *et al.*, 1996; Scott *et al.*, 2000). Vitamin  $B_x$  has ultra violet absorbing properties and is subsequently used in local anesthetic agents and sunscreen products to prevent the development of sunburn and skin cancer from excess ultraviolet

light exposure (Levee *et al.*, 1981; Ludwig, 1991; Zarafonetis *et al.*, 1988). However, it is now seldom used as sunscreen products because it had been discovered from animal studies with Vitamin  $B_x$  in the early 1980s that there may be an increased risk of *ultra violet* cellular damage (Levee *et al.*, 1981; Osgood *et al.*, 1982).

Paracetamol is chosen as the second ligand due to its mild analgesic and weak anti-inflammatory activity(Larson *et al.*, 2005). Furthermore being a phenolic molecule, it has good antioxidant properties which could be utilized in developing metallo-drugs for treatment of pain, essential metal and vitamin deficiencies (Osowole *et al.*, 2014; Roberts and Morrow, 2001).

Thus, the objectives of this work are to design and characterize mixed drug metal complexes of Vitamin Bx and Paracetamol, with potential antioxidant properties. Secondly, assess the suitability of Vitamin Bx and Paracetamol as ligands in forming metal complexes with spincrossover, antiferromagnetism and ferromagnetism temperature magnetic bv room moment measurements; and predicting the geometry of the metal complexes based on IR and electronic spectroscopic analysis. These compounds are new, and a continuation of the research activities of our group on the design of potent metallo-drugs as chemotherapeutic agents in pain management and essential metal/vitamin deficiencies (Agbaje et al., 2015; Osowole et al., 2014; Osowole et al., 2015a; Osowole et al., 2015b)

# MATERIALS AND METHODS Materials and Reagents

Reagent grade para-aminobenzoic acid, DPPH (1,1-diphenyl-2-picryl-hydrazyl), ascorbic acid, manganese(II) sulphate monohydrate, iron(II) sulphate heptahydrate, cobalt(II) chloride hexahydrate, nickel(II) chloride hexahydrate, copper(II) sulphate pentahydrate and zinc(II) sulphate heptahydrate were obtained from Aldrich and BDH chemicals, while Paracetamol was freely collected from Bentos pharmaceutical products limited, new garage, Ibadan, Nigeria and were used as received. Solvents were purified by distillation.

#### SYNTHESIS

# Preparation of [Mn(HL)(HL<sup>1</sup>)SO<sub>4</sub>] and other metal complexes:

The metal (II) complexes were synthesized according to the procedure of Agbaje et al., (2015). 0.57 g ( $4.16 \times 10^{-3}$  moles) of Vitamin Bx. (HL) and 0.63 g (4.16 x  $10^{-3}$  moles) of Paracetamol, (HL<sup>1</sup>) were dissolved in 20 mL of methanol. To the resulting homogenous solution, 0.70 g (4.16 x  $10^{-3}$  moles) of the Mn(II) sulphate monohydrate was added while stirring at room temperature. After stirring for 30 minutes, the solution was buffered with 8-9 drops of ammonia up to pH of 9. The concentrated resulting homogenous solution was left on continuous stirring for 3 hours during which the product formed. The white precipitate obtained was filtered, washed with methanol and dried over silica gel. The same procedure was used for the preparation and isolation of Fe(II), Cu(II), Zn(II) complexes from their sulphate salts; and Co(II), Ni(II) complexes from their chloride salts respectively.

### **Physical measurements**

The UV-visible spectra of the metal complexes were recorded using UV-1800/SHIMADZU UVspectrophotometer personal computer (PC) scanning and infrared spectra were recorded on a CARY 630 FTIR in the range 4000-650 cm<sup>-1</sup>. The room temperature magnetic moment susceptibilities measurement were determined using a Sherwood susceptibility balance MSB Mark 1 at 299 K and diamagnetic corrections were calculated using Pascal's constant. The melting points and decomposition temperature were determined using Stuart SMP 10 machine while molar conductivity measurement of 1x 10<sup>-3</sup> M solutions of DCM (dichloromethane) were obtained using DDS-307A conductivity meter, and percentage metal was determined using EDTA by complexometric titration.

#### Antioxidant assay

The antioxidant activities of Vitamin Bx, Paracetamol and their metal complexes were studied spectrophotometrically by DPPH method. DPPH(1,1-diphenyl-2-picryl-hydrazyl) dissolves in DMSO to give a violet solution, which, upon reduction by an antioxidant, changes to yellow. A solution of 0.4 mM DPPH in DMSO was prepared and 1.0 mL of this solution was mixed with 1.0 mL DMSO solutions of the metal(II) complexes with a single concentration of 100  $\mu$ g mL<sup>-1</sup>. The reaction mixture was stirred thoroughly and left in the dark at room temperature for 30 min. The absorbance of the mixture was measured spectrophotometrically at 517 nm. Ascorbic acid (vitamin C) was used as the standard drug. The actual decrease in absorption was measured against that of the control. All tests and analyses

were run in triplicate and the results obtained were averaged, and percentage scavenging inhibition of DDPH ability was expressed as:

% scavenging inhibition =  $\{(Ac - As)/Ac\} \times 100....(1)$ 

where Ac is the absorbance of DPPH radical + dimethylsulphoxide, and As is the absorbance of DPPH radical + sample [test samples/standard].

### **RESULTS AND DISCUSSION** Analytical data

The reaction of Vitamin  $B_x$  (HL) and Paracetamol (HL<sup>1</sup>) with the hydrated metal(II) sulphates (Mn, Fe, Cu, Zn) and chlorides (Co, Ni) respectively produced coloured complexes of low to good yields (10-70%) according to the generalized equations below:

All the metal complexes had expected colour due to d-d transition, and the Zn(II) complex was expectedly white due to its  $d^{10}$  configuration. The ligands, Vitamin Bx and Paracetamol melted at 188-190°C, while their metal(II) complexes decomposed in the range 212-252 °C, due to coordination.

The formation of the metal complexes was corroborated by formulated masses, since experimental values of the percentage metal analysis were very close to the theoretical values. In addition, the presence of metal-ligand bands in the IR and solid reflectance spectra of the metal complexes, and its absence in the spectra of both Vitamin Bx and Paracetamol, also confirmed coordination.

Olanrewaju and Osowole; FUTA J. Res. Sci., Vol. 13 (2), October, 2017: 190 -198

Complexes	Formula	Colour	M.Pt	% yield	%Metal	^m	µeff.
	mass		$(^{\circ}C)$		Theo.(Exp)		(B.M)
HL	137.14	Off-white	188-190	-	-	-	D
$\mathrm{HL}^1$	151.15	White	170-172	-	-	-	D
$[Mn(HL)(HL^1)SO_4]$	439.25	White	218*	30.0	12.53(12.54)	21.0	0.7
$[Fe(HL)(HL^1)SO_4]$	440.16	Brown	228*	30.0	12.73(12.77)	20.9	3.8
$[Co(HL)(HL^1)Cl_2]$	418.22	Brown	212*	10.0	14.11(14.16)	21.1	5.95
$[Ni(HL)(HL^1)Cl_2]$	418.00	Green	214*	40.0	14.06(14.09)	21.2	3.1
$[Cu(HL)(HL^1)SO_4]$	447.85	Green	237*	70.0	14.59(14.29)	21.2	2.30
$[Zn(HL)(HL^1)SO_4]$	449.68	White	252*	50.0	14.48(14.82)	21.2	D

**Table 1:** Analytical data of the ligands and their metal(II) complexes

HL = Vitamin Bx; HL<sup>1</sup> = Paracetamol; M.pt = Melting point; \* = decomposition temperature; Theo. = Theoretical; Exp = Experimental; ^m = Molar conductance ( $\Omega^{-1}$ cm<sup>2</sup>mol<sup>-1</sup>); µeff = effective magnetic moment; B.M = Bohr Magneton; D = Diamagnetic

# Solubility and molar conductance measurements

The complexes were insoluble in diethyl ether, slightly soluble in methanol and ethanol but showed good solubility in DMSO and water. The metal complexes had molar conductivities values in the range 20.9 - 21.2 ohm<sup>-1</sup>cm<sup>2</sup>mol<sup>-1</sup> in dichloromethane(DCM) confirming their covalent nature, since values in the range 60 - 118 ohm<sup>-1</sup>cm<sup>2</sup>mol<sup>-1</sup> is expected for 1:1 electrolyte (Ekennia *et al.*; 2015).

#### Electronic spectra and magnetic moments

The electronic spectra of the compounds were presented in Table 2. Their ultraviolet spectra were characterized by strong absorption bands  $27,320 - 29,240 \text{ cm}^{-1}$ ,  $32,360 - 39,400 \text{ cm}^{-1}$  and  $40,000 - 40,920 \text{ cm}^{-1}$  assigned to  $n \rightarrow \pi^*$ ,  $\pi \rightarrow \pi^*$  and charge transfer respectively. The Mn(II) complex exhibited a strong absorption band at 24,150 cm<sup>-1</sup> ( $\epsilon = 500$ ) assigned to  ${}^2\text{T}_{2g} \rightarrow {}^2\text{A}_{1g}$  transition, of a low spin octahedral geometry. An observed room temperature moment of 0.7 B.M, instead of an expected value of ~2.0 B.M was suggestive of a dimeric structure with strong antiferromagnetism operating through a Mn-Mn bond (Saha *et al.*, 2000).

The Fe(II) complex on the contrary, had two absorption bands at 16,780 cm<sup>-1</sup> ( $\epsilon = 300$ ) and

21,070 cm<sup>-1</sup> ( $\varepsilon = 500$ ) typical of high spin and low spin octahedral geometry and were assigned to  ${}^{5}T_{2g} \rightarrow {}^{5}E_{g}$  and  ${}^{1}A_{1g} \rightarrow {}^{1}T_{2g}$  transitions. High spin octahedral Fe(II) complexes should have moments within the range 5.0 - 5.5 B.M and low spin octahedral Fe(II) are expected to be diamagnetic. On the contrary, a moment of 3.8 B.M was observed for Fe(II) complex, which was indicative of spin-crossover, that is an equilibrium between the high spin and low spin octahedral geometry. This is a common feature within Fe(II) systems (Olguin and Brooker, 2011).

The Co(II) complex exhibited a lone band at 23,280 cm<sup>-1</sup> ( $\varepsilon = 1.0 \times 10^3$ ), consistent with a low spin octahedral geometry and was assigned to  ${}^2E_g \rightarrow {}^2T_{2g}$  transition. Low spin octahedral Co(II) complexes usually exhibit moments in the range 1.9-2.9 B.M., but in this study a moment of 5.95 B.M was observed, indicative of a dimeric octahedral cobalt (II) with bridging chloride such that each Co(II) atom had a moment of ~ 2.98 B.M (Barefield *et al.*, 1968; Goodwin, 2004).

Similarly, the Ni(II) complex had two absorption bands at 13,150 cm<sup>-1</sup> ( $\epsilon = 250$ ) and 14,980 cm<sup>-1</sup> ( $\epsilon = 400$ ) typical of six coordinate, high spin octahedral geometry. These bands were assigned as  ${}^{3}A_{2g} \rightarrow {}^{3}T_{2g}$  and  ${}^{3}A_{2g} \rightarrow {}^{3}T_{1g}$  transitions. Room temperature magnetic moments in the range 2.8-3.3 B.M are expected for high


spin octahedral Ni(II) complexes. Thus, an observed moment of 3.10 B. M corroborated this geometry (Ohtsu and Tanaka, 2004).

The Cu(II) complex expectedly had a single band at 14,960 cm<sup>-1</sup> ( $\varepsilon = 1000$ ), typical of octahedral geometry, since octahedral Cu(II) complexes usually have lone band above 10,000 cm<sup>-1</sup> whereas tetrahedral Cu(II) complexes had their lone band below 10,000 cm<sup>-1</sup>. The transition was assigned as  ${}^{2}E_{g} \rightarrow {}^{2}T_{2g}$  transition (Manonmani *et al.*, 2011). A complimentary moment of 2.30 B.M was observed since mononuclear copper(II) complexes, regardless of stereochemistry usually

have moments in the range 1.9-2.20 B.M complex (Osanai et al., 2006).

The Zn(II) complex had its  $M\rightarrow L$  CT transition at 12,840 cm<sup>-1</sup> ( $\epsilon = 150$ ) and 16,780 cm<sup>-1</sup> ( $\epsilon = 250$ ) respectively since d-d transition was not possible. The complex was expectedly essentially diamagnetic with octahedral geometry (Raman *et al.*, 2004).

Conclusively, the ligands, Paracetamol and Vitamin Bx, were suitable designer ligands for formation of low spin complexes with strong magnetic interactions, that is, antiferro magnetism and spin crossover respectively.






Figure1: Proposed structure for the Co(II) and Mn(II) complexes




Figure 2: Proposed structure for Ni(II) and M(II) complexes: M= Fe, Cu and Zn

#### **Infrared Spectra**

The relevant bands are presented in Table 2. The bands at 3360 cm<sup>-1</sup> and 3382 cm<sup>-1</sup> in Vitamin Bx and Paracetamol were assigned as v(OH) (Osowole et al., 2014; Osowole et al., 2015c), while the bands at 3319 cm<sup>-1</sup>, 3457 cm<sup>-1</sup> and 3377 cm<sup>-1</sup> were assigned to v(NH) of Paracetamol and Vitamin Bx respectively (Sangita *et al.*, 2012; Shipra *et al.*, 2015). The v(OH) bands of both ligands, were observed shifted in the metal complexes to the range 3368-3060 cm<sup>-1</sup> due to coordination of the phenolic oxygen and carboxylate atoms of Paracetamol and Vitamin Bx to the metal ion respectively. In contrast, the

v(NH) bands were shifted in the metal complexes to 3556-3060 cm<sup>-1</sup> due to hydrogen bonding and not coordination since M-N-bands were not observed (Sayyed *et al.*, 2014). The v(C=O) bands of Vitamin Bx and Paracetamol were seen in the range 1657-1571 cm<sup>-1</sup> and 1649-1560 cm<sup>-1</sup>. These were bathochromic/hypochromic shifted in the metal complexes to the range 1707-1541 cm<sup>-1</sup> due to coordination (Beyramabadi *et al.*, 2011). The observance of M-O bands in the metal complexes at 690-650 cm<sup>-1</sup>, further confirmed coordination. However, v(M-CI) was not observed because it was outside the range of the equipment.

 Table 2: Infra-red and electronic spectra data of the metal(II) complexes

Complex	v(OH)	v(NH <sub>2</sub> )	v(C=O)	v(M-O)	Electronic spectra (cm <sup>-1</sup> )
HL	3360m	3457s	1657s 1597s 1571s		27,320 29,240
		3377m			
$\mathrm{HL}^1$	3382m	3319m	1649s 1610s 1560s		32,890
$[Mn(HL)(HL^1)SO_4]$	3220m	3465m	1630s 1602s 1579s	669s	24,150 32,360 40,000
		3353m			
$[Fe(HL)(HL^1)SO_4]$	3214b	3524m	1597s 1541s	650s	16,780 21,070 28,410
					40,130
$[Co(HL)(HL^1)Cl_2]$	3368b	3556b	1653s 1608s1560s	657s	23,280 33,850 37,710
$[Ni(HL)(HL^1)Cl_2]$	3289b	3360b	1649s 1602s 1560s	662s	13,150 14,980 39,400
		3319m			
$[Cu(HL)(HL^1)SO_4]$	3060b	3060b	1701s 1612s 1571s	690s	14,960 34,200 40,420
$[Zn(HL)(HL^1)SO_4]$	3256b	3314m	1707s 1679s 1573s	655s	12,840 16,780 40,920
		3256b			

 $HL = Vitamin Bx, HL^1 = Paracetamol, b = broad, m = medium, s = sharp$ 

### **DPPH Free radical scavenging activity**

Antioxidants when present in the body may offer protection against cancers, alzheimer's and Parkinson's diseases (Halliwell *et al.*, 1984). DPPH acts by accepting an electron from test compounds, and gets converted into a stable molecule. In this study, it was observed that Co(II) and Zn(II) complexes had highest percentage inhibition of ~98% which was higher than that of the positive standard, Vitamin C, with an activity of `~88%. The scavenging ability of the metal complexes decrease in the order; Zn ~Co> Ni> Mn>Fe> Cu. Thus, these compounds had potential as health protecting factor.

Table 5. Antioxidant properties of the metal complexes							
Complex	<b>Average</b> ± <b>SD</b>	% inhibition					
$[Mn(HL)(HL^1)SO_4]$	$0.040 \pm 0.0027$	66.27					
$[Fe(HL)(HL^1)SO_4]$	$0.038 \pm 0.0012$	63.53					
$[Co(HL)(HL^1)Cl_2]$	$0.059 \pm 0.0015$	98.33					
$[Ni(HL)(HL^1)Cl_2]$	$0.044 \pm 0.0012$	72.38					
$[Cu(HL)(HL^1)SO_4]$	$0.019 \pm 0.0015$	32.03					
$[Zn(HL)(HL^1)SO_4]$	$0.059 \pm 0.0006$	98.35					
Standard (Ascorbic acid)	$0.053 \pm 0.0026$	87.66					

 Table 3: Antioxidant properties of the metal complexes

HL = Vitamin Bx,  $HL^1 = Paracetamol$ , SD = Standard Deviation, % = percentage

#### CONCLUSION

Some Mn(II), Fe(II), Co(II), Ni(II) Cu(II) and Zn(II) complexes of mixed drugs, Vitamin Bx and Paracetamol, were synthesized and characterized by solubility, percentage metal, melting points, room temperature magnetic moments, conductivity, infrared and electronic spectra measurements. All the metal complexes adopted 6-coordinate octahedral geometry and the conductance measurements revealed that they are non electrolytes. Furthermore the metal complexes were magnetically dilute, with the exceptions of Fe(II), Mn(II) and Co(II) complexes which exhibited spin-cross over and antiferromagnetism respectively. The antioxidant studies on the metal complexes showed that all the metal complexes had very good percentage inhibition in the range 98.35-63.53, with the exception of Cu(II) complex with the lowest percentage inhibition of 32.03, suggesting them as potential agents for chronic ailments risk reduction.

#### ACKNOWLEDGEMENT

The authors thanked the University of Ibadan, Ibadan, Nigeria and Bowen University, Iwo for a sabbatical leave and research chemicals/facilities respectively.

### REFERENCES

Agbaje, O.B.A., Osowole, A.A., Malumi, E.O

and Wakil, S.M. (2015). Synthesis, spectroscopic characterization,

antimicrobial and antioxidant properties of some metal(II) complexes of mixed ligands-Riboflavin and 4-aminobenzoic acid. Research and Reviews: Journal of Chemistry; 4(1): 1-7.

# **Barefield, E.K., Busch, D.H and Nelson, S.M.** (1968). Cobalt and nickel complexes having anomalous magnetic moments. Quarterly

Reviews; 22:457. Beyramabadi, S.A., Eshtagh-Hosseini, H., Housaindokht, M.R and Morsali, A. (2011).

Synthesis, experimental and theoretical characterization of Cu(II) complex of 2-chloropyrimidine. Sci. Res. Ess.; 6(20): 4341-4346.

# **Cossins, E.A.** (2000). The fascinating world of folate and one-carbon metabolism. Canadian Journal of Botany; 78: 691-708.

Ekennia, A.C., Onwudiwe, D.C and Osowole,
A.A. (2015). Synthesis, Spectral, thermal stability and antibacterial studies of copper, nickel and cobalt complexes of N-methyl-N-phenyl dithiocarbamate. Journal of Sulfur Chemistry; 36(1): 96-104.

- Goodwin, H.A. (2004). Spin Crossover in Cobalt(II) Systems. Top. Curr. Chem.; 234:23-27.
- Green, J.M., Nichols, B.P and Matthews, R.G. (1996). in Escherichia coli and Salmonella: Cellular and Molecular Biology, ed. Neidhardt,

F.C. (Am. Soc. Microbiol., Washington, DC), pp. 665-673.

Halliwell, B and Gutteridge, J.M.C. (1984).

Oxygen toxicology, oxygen radicals, transition metals and disease. Biochem Journal; 219: 1-4.

Larson, A.M., Polson, J. and Fontana, R.J.

(2005). Acetaminophen induced acute liver failure: results of aUnited States multicenter, prospective study. Hepatology; 42(6):1364–72.

### Levee, G.J., Sayre, R.M and Marlowe, E.

(1981). P-aminobenzoic acid as a sunscreen and its behaviour on the skin. International Journal of Cosmetic Science; 3: 49-55.

Manonmani, J., Thirumurugan, R.,

Kandaswamy, M., Kuppayee, M., Raj, S.S.S,Ponnuswamy, M.N., Shanmugan, G and Fun, H.K. (2000). Synthesis of mononuclear nickel(II) and copper(II) complexes using compartmental ligands: X-ray and electrochemical studies. Polyhedron; 19: 2011-2018.

**Ohtsu, H and Tanaka, K.** (2004). Equilibrium of low- and high-spin states of Ni(II) complexes controlled by the donor ability of the bidentate ligands. Inorganic Chemistry;43(9): 3024-30.

Olguín, J and Brooker, S. (2011). Spin crossover active iron(II) complexes of selected pyrazole-pyridine/pyrazine ligands. Coordination Chemistry Reviews; 255: 203– 240.

Osanai, K., Okazawa, A., Nogami, T and

**Ishida, T.** (2006). Strong ferromagnetic exchange couplings in Cu(II) and Ni(II) complexes with a paramagnetic tridentate chelate ligand, 2,2-bipyridin-6-yl tert-butyl nitroxide. America Journal of Chemical Society; 128:14008-9.

### Osgood, P.J., Moss, S.H and Davies, D.J.G.

(1982). The Sensitization of Near-Ultraviolet Radiation Killing of Mammalian Cells by the Sunscreen Agent Para-aminobenzoic Acid. Journal of Investigative Dermatology; 79(6): 354–7. **Osowole, A.A., Agbaje, O.B.A and Ojo, B.O.** (2014): Synthesis, characterization and antibacterial properties of some heteroleptic metal(II) complexes of Paracetamol and Vanillin. Asian Journal of Pharmaceutical and Clinical Research; 7(3): 145-149.

**Osowole, A..A., Malumi, E.O and Odutemu, A.E.** (2015a). Synthesis, Magnetic, Spectral and Antioxidant Properties of Some Metal(II) Mixed-Drug Complexes of Aspirin and Vitamin B<sub>3</sub>. Research and Reviews: Journal of Chemistry; 4(1): 60-65.

Osowole, A.A., Malumi, E.O., Wakil, S.M and Alao, O.K. (2015b). Synthesis characterization, antioxidant and antimicrobial activities of some mixed-drug metal(II) complexes of Vitamins B<sub>2</sub> and B<sub>3</sub>. International Journal of Applied Medical Sciences; 1(2): 88-97.

Raman, N., Ravichandran, S and Thangaraja,
C. (2004). Cu(II), Co(II), Ni(II) and Zn(II) complexes of Schiff base derived from benzil-2,4- dinitrophenyl hydrazone with aniline.
Journal of Chemical Society (Indian Academic Society); 4:116–215.

Roberts, L.J and Morrow, J.D. (2001).

Analgesic-antipyretic and anti-inflammatory agent sand drugs employed in the treatment of gout. In Gilman, Alfred; Goodman, Louis Sanford; Hardman, Joel G.; Limbird, Lee

E. Goodman & Gilman's the pharmacological basis of therapeutics. New York:McGraw-Hill; pp. 687–732.

## Saha, A., Majumda, P and Goswami, S.

(2000). Low spin Mn(II) and Co(II) complexes of N-aryl-2-pyridylazophenylamines; New tridentate N,N,N-donors derived from cobalt mediated aromatic ring amination of 2-(phenylazo)pyridine. Crystal structure of manganese(II) complex. Journal of Chemical Society (Dalton Transactions) 11: 1703-1708.

## Sangita, P.K., Farhad, M.A., Sania, S.,

MdZakir,S.,Mohammad,A.HandMohammad,S.A. (2012).Study ofDifferential Scanning Calorimetry of complex

of Magnesium Sulfate with Aspirin, Paracetamol and Naproxen. Bangladesh Pharmaceutical Journal; 15(1): 7-12.

- **Sayyed, H., Shaikh, A and Mazahar, F.** (2014). Potentiometric studies of p-amino benzoicacid with transition metal ions. World journal of pharmacy and pharmaceutical sciences; 3(5): 632-635.
- Scott, J.M., Rébeillé, F and Fletcher, J. (2000). Folic acid and folates: the feasibility for nutritional enhancement in plant foods. Journal

of the Science of Food and Agriculture; 80, 795-824.

- Shipra, B., Falguni, K and Kapil, B. (2015). Physicochemical study of p-amino benzoic acid. International Journal of Basic and Applied Chemical Sciences; 5(3): 24-29.
- Zarafonetis, C.J., Dabich, L., Skovronski, J.J.,
  Devol, E.B., Negri, D., Yuan, W and Wolfe,
  R. (1998). Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clinical Experimental Rheumatology; 6: 261-8.